We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Arena Initiates Phase 1b Trial for Autoimmune Disease Drug
News

Arena Initiates Phase 1b Trial for Autoimmune Disease Drug

Arena Initiates Phase 1b Trial for Autoimmune Disease Drug
News

Arena Initiates Phase 1b Trial for Autoimmune Disease Drug

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Arena Initiates Phase 1b Trial for Autoimmune Disease Drug"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Arena Pharmaceuticals, Inc.  announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases.

This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.

"We continue to make progress in advancing our novel pipeline of internally discovered drug candidates, and remain committed to our vision of leading the industry in the discovery, development and commercialization of GPCR-directed medicines," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer.

Advertisement